Not Signed In - For Patients with Hypertension and Left Ventricular Hypertrophy, FDA Approves HYZAAR®
Sun, 17 Apr 2005 06:00 PM EST
... Merck & Co, Inc announced that the US Food and Drug Administration (FDA) has approved another new indication for HYZAAR®, Merck's fixed-dose combination antihypertensive drug (losartan potassium-hydrochlorothiazide tablets)... click link for more info. ...
Related Topics
- Left ventricular hypertrophy (enlargement) caused by the extra work of pushing blood through the narrowed valve
- Pulmonary Hypertension
- Intracranial Hypertension
- Hypertension
- Arrhythmia
- Abdominal Pain
- Hypertrophy
- Prostate, Benign Hypertrophy
- Pain, Chest
- Chest Pain
- Seizures (in about half of patients)
- What Your Female Patients Want to Know About Bladder Control
- Vaccinations For HIV/AIDs Patients
- Tacrolimus ointment
- Ventricular fibrillation
- Ventricular tachycardia
- Smoking Cessation and Continued Risk in Cancer Patients
- Premature Ventricular Contractions
- Ventricular Septal Defects
- Ventricular septal defect
email this page
print this page
bookmark this page
feedback on this page
